The near future: Improving the activity of rifamycins and pyrazinamide

Tuberculosis

Volumn 90, Issue 3, 2010, Pages 177-181

  Mitchison, D A ^a   Fourie, P B ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Medicine in Need South Africa   (South Africa)

Author keywords

Drug inhalation; Pyrazinamide; Pyrazinoic acid; Rifamycins; Trojan particles

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; AMINOSALICYLIC ACID; CAPREOMYCIN; ISONIAZID; NANOPARTICLE; POLYGLACTIN; PYRAZINAMIDE; PYRAZINOIC ACID; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE; WHEAT GERM AGGLUTININ;

AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG STABILITY; DRUG STORAGE; DRY POWDER; FIRST PASS EFFECT; FREEZE DRYING; HUMAN; LIVER TOXICITY; LUNG ALVEOLUS; LUNG TUBERCULOSIS; NANOEMULSION; NANOENCAPSULATION; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHELF LIFE; SPRAY DRYING;

ADMINISTRATION, INHALATION; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; HUMANS; LUNG; MULTICENTER STUDIES AS TOPIC; PARTICLE SIZE; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 77952584170     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2010.03.005     Document Type: Review

References (49)

1. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 20 (1972 May) 1079-1085
2. Mitchison D.A. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4 9 (2000) 796-806
3. Mitchison D.A. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 2 8 (1998) 612-615
4. Tam C.M., Chan S.L., Lam C.W., Leung C.C., Kam K.M., Morris J.S., et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Am J Respir Crit Care Med 157 6 Pt 1 (1998) 1726-1733
5. Tuberculosis Trials Consortium. Once-weekly rifapentine and INH versus twice-weekly rifampin and INH in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons. Lancet 360 (2002) 528-534
6. Diacon A.H., Patientia R.F., Venter A., van Helden P.D., Smith P.J., McIlleron H., et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 51 8 (2007) 2994-2996
7. Peloquin C. What is the 'right' dose of rifampin?. Int J Tuberc Lung Dis 7 1 (2003) 3-5
8. Sirgel F.A., Botha F.J.H., Parkin D.P., Van de Wal B.W., Donald P.R., Clark P.K., et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts. A new method of drug assessment. J Antimicrob Chemother 32 6 (1993) 867-875
9. Mehta J.B., Shantaveerapa H., Byrd Jr. R.P., Morton S.E., Fountain F., and Roy T.M. Utility of rifampin blood levels in the treatment and follow up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 120 5 (2001) 1520-1524
10. Zhang T., Zhang M., Rosenthal I.M., Grosset J.H., and Nuermberger E.L. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2009 Sep 3) [Epub ahead of print]
11. Grumbach F., and Rist N. Experimental antitubercular activity of rifampicin, a derivative of rifampicin SV. Rev Tuberc Pneumol (Paris) 31 6 (1967) 749-762 [French]
12. Dickinson J.M., and Mitchison D.A. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 51 1 (1970) 82-94
13. Keung A., Eller M.G., McKenzie K.A., and Weir S.J. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int J Tuberc Lung Dis 3 5 (1999) 437-444
14. Sirgel F.A., Fourie P.B., Donald P.R., Padayatchi N., Rustomjee R., Levin J., et al., the Rifapentine EBA Collaborative Study Group. The early bactericidal activities of rifampicin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 172 1 (2005) 128-135
15. Lacroix C., Hoang T.P., Nouveau J., Guyonnaud C., Laine G., Duwoos H., et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 36 4 (1989) 395-400
16. Zhang Y., and Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7 1 (2003) 6-21
17. Zhang Y., Wade M.M., Scorpio A., Zhang H., and Sun Z. Mode of action of pyrazinamide disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52 5 (2003) 790-795
18. Zhang Y., Permar S., and Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51 1 (2002) 42-49
19. Hu Y., Coates A.R., and Mitchison D.A. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 10 3 (2006) 317-322
20. Yew W.W., and Leung C.C. Antituberculosis drugs and hepatotoxicity. Respirology 11 6 (2006) 699-707 [Review]
21. Matthews J.H. Pyrazinamide and Isoniazid used in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 81 (1960) 348-351
22. McCune Jr. R.M., McDermott W., and Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104 5 (1956) 763-802
23. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 115 (1977) 727-735
24. McDermott W., and Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 70 4 (1954) 748-754
25. Jindani A., Doré C.J., and Mitchison D.A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167 (2002) 1348-1354
26. Fox W., Ellard G.A., and Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3 10 (1999) S231-S279
27. Konno K., Feldmann F.M., and McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 95 (1967) 461-469
28. Denkin S., Volokhov D., Chizhikov V., and Zhang Y. Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. J Med Microbiol 54 Pt 12 (2005) 1127-1131
29. Fiegel J., Garcia-Contreras L., Thomas M., VerBerkmoes J., Elbert K., Hickey A., et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res 25 (2008) 805-811
30. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58 (2006) 1030-1060
31. Garcia-Contreras L., Fiegel J., Telko M.J., Elbert K., Hawi A., Thomas M., et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 51 (2007) 2830-2836
32. Tsapis N., Bennett D., O'Driscoll K., Shea K., Lipp M.M., Fu K., et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis 83 (2003) 379-385
33. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., and Prasad B. Poly(dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52 (2003) 981-986
34. Sharma A., Sharma S., and Khuller G.K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 54 (2004) 761-766
35. Zahoor A., Sharma S., and Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 26 (2005) 298-303
36. Sung J.C., Pulliam B.L., and Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25 (2007) 563-570
37. Tsapis N., Bennett D., Jackson B., Weitz D.A., and Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A 99 (2002) 12001-12005
38. Scheuch G., Kohlaeufl M.J., Brand P., and Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 58 (2006) 996-1008
39. Smola M., Vandamme T., and Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine 3 (2008) 1-19
40. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release 86 (2003) 131-144
41. Gomez-Gaete C., Fattal E., Silva L., Besnard M., and Tsapis N. Dexamethasone acetate encapsulation into Trojan particles. J Control Release 128 (2008) 41-49
42. Wendorf J., Singh M., Chesko J., Kazzaz J., Soewanan E., Ugozzoli M., et al. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci 95 (2006) 2738-2750
43. Muttil P., Wang C., and Hickey A.J. Inhaled drug delivery for tuberculosis therapy. Pharm Res 26 (2009) 2401-2416
44. Pandey R., Zahoor A., Sharma S., and Khuller G.K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 83 6 (2003) 373-378
45. Garcia-Contreras L., Sethuraman V., Kazantseva M., Godfrey V., and Hickey A.J. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother 58 (2006) 980-986
46. Kayser O., Olbrich C., Croft S.L., and Kiderlen A.F. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res 90 Suppl. 2 (2003 Jun) S63-S70
47. Pandey R., Sharma S., and Khuller G.K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) 85 5-6 (2005) 415-420
48. El-Ridy M.S., Mostafa D.M., Shehab A., Nasr E.A., and Abd El-Alim S. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm 330 1-2 (2007) 82-88
49. Justo O.R., and Moraes A.M. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv 10 3 (2003) 201-207